16 September 2026 editorial review · Trial
Autologous insulin-producing mesenchymal stem cells in youth: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT06951074; RECRUITING; updated 2025-04-30; enrollment 20 (ESTIMATED); results not posted.
Endpoint comparison: Insulin producing mesenchymal stem cells efficacy in insulin production in vitro (1 year); Insulin producing mesenchymal stem cells efficacy in insulin production in vitro (1 year); Insulin producing mesenchymal stem cells efficacy in insulin production in vivo (1 year).
Sources for this record: NCT06951074: Autologous insulin-producing mesenchymal stem cells in youth (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.